Foundation Care - Study Abstracts

Please send me information regarding the following:

Albuterol

Efficient Delivery of Albuterol with a New Vibrating Mesh Nebulizer (eFlow)

Aztreonam

Efficacy and Safety of Inhaled Pseudomonas in Cystic Fibrosis

Amikacin

Aerosolized Amikacin Case Report
Aerosolized Amikacin in the Treatment of Pseudomonas Pneumonia in the Nursing Home Setting

Colistmethate

Performance Characteristics of Colistimethate Sodium Solutions (Colistin) Delivered by Jet Nebulizers Compared to the eFlow® SCF Electronic Nebulizer
Use of Colistin in the Treatment of Multiple-Drug-Resistant Gram-Negative Infections
Stability of Colistin Methanesulfonate in Pharmaceutical Products and Solutions for Administration to Patients

Trio™, (formerly eFlow® SCF)

FDA: eFlow 510K letter
Means to Optimized Drug Delivery from a Novel Electronic Inhaler (eFlow®)
“Does repeated disinfection of the eFlow rapid® nebulizer affect in vitro performance?”

Glutathione

A Pilot Study of the Effect of Inhaled Buffered Reduced Glutathione on the Clinical Status of Patients with Cystic Fibrosis
A Radical Treatment for Cystic Fibrosis Lung Disease
Improvement of Alveolar Glutathione & Lung Function but not Oxidative State in Cystic Fibrosis

Hypertonic Saline

A Controlled Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Mucus Clearance & Lung Function in Cystic Fibrosis with Hypertonic Saline
Restoring Airway Surface Liquid in Cystic Fibrosis
Aerosol Characterization of Hypertonic Saline (Hyper-Sal 3.5% and 7%) in Jet Nebulizers and the eFlow.

L-Arginine

PARI’s eFlow in Cystic Fibrosis Clinical Trial of L-Arginine

Pulmozyme

Increased Efficiency of Pulmozyme Delivery by the Novel eFlow Electronic Nebulizer

Tobramycin

Comparison of Tobramycin Serum Plasma Levels in Five CF Patients After Inhalation Via a PARI LC PLUS® Nebulizer and Via eFlow®, a Novel Electronic Inhaler
Demonstration of In-Vitro Equivalence and Shorter Nebulization Time with eFlow® SCF and TOFIN™ (150mg/1.5ml) compared to the PARI LC PLUS® and TOBI® (300mg/5ml)
Journal of CF: Comparison of Tobramycin Serum Plasma Levels in Five CF Patients After Inhalation of TOBI® via a PARI LC PLUS® Nebulizer and Via eFlow®, a Novel Electronic Inhaler
Ways for an In-Vitro/In-Vivo Correlation for Predicting Lung Deposition of Aqueous Nebulized Tobramycin Formulations Linking Breath Simulation & Cascade Impaction Methods
A Rapid Way to Deliver High Doses of Tobramycin to the Airways of Adult and Pediatric Patients with Cystic Fibrosis.
Higher Tobramycin Concentration and Vibrating Mesh Technology Can Shorten Antibiotic Treatment Time in CF.

Other

“Aerosolized Antibotics” from the American College of Chest Physicians
Aerosol Therapy to Treat Burkholderia Cepacia Complex
“Corus Pharma, Inc.” from Nursing Home & Elder Business Week
Effect of Nebulizer Type and Antibiotic Concentration on Device Performance
Formulation of Aerosolized Theraputics
Granulocyte-Macrophage Colony-Stimulating Factor & Lung Immunity in Pulmonary Alveolar Proteinosis
Impact of the Nebulization Principle on the Biological Activity of Labile Formulations Containing Liposomes, Peptides, Proteins
PARI’s eFlow Nebulizer Used in Alnylam Clinical Trial for Respiratory Syncytial Virus; New Drug Based on RNAi Technology
PARI & Kamada Collaborate to Develop Inhaled Alpha-1 Antitrypsin
Pathophysiology & Management of Pulmonary Infections in Cystic Fibrosis
Airway Rehydrating Agents for the Treatment of CF: Past, Present, and Future



	*Indicated Required Field
First Name:*
Last Name:*
E-mail:*
City:*
State:*	Zip:*
Phone:*